Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2018

View Archived Issues

FDA grants orphan drug designation to tenalisib for treatment of cutaneous T-cell lymphoma

Allogene Therapeutics finalizes CAR T therapy asset transaction with Pfizer

Novel DEC cell therapy demonstrates efficacy in mouse model of Duchenne muscular dystrophy

Ionis licenses drug candidate for NASH to AstraZeneca

Gruenenthal enters nonopioid drug collaboration with KU Leuven

ALT-803/nivolumab combination shows antitumor activity in non-small cell lung cancer study

Novel miRNAs found upregulated in schizophrenia

Oncology Venture Sweden agrees to inlicense dovitinib from Novartis

DMC recommends continuation of phase III OPTIMA study of ThermoDox

Bayer presents novel muscarinic M2 receptor positive allosteric modulators

Topline data presented from phase IIa study of THX-110 in Tourette syndrome

Novel bromodomain inhibitors identified at the University of Michigan

Janssen describes novel menin-MLL interaction inhibitors

Primary endpoint met in phase III KEYNOTE-042 study

AstraZeneca discovers new phosphatidylinositol 3-kinase inhibitors

RegeneRx announces outcome of FDA discussions regarding the development of RGN-259

BeiGene identifies new IDO-1/TDO inhibitors

RP-5063 granted FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis

STEADFAST phase IIIa study of azeliragon does not meet coprimary efficacy endpoints

Additional data presented from phase II trial of brilacidin-OM in severe oral mucositis

SELECT-COMPARE phase III study meets all primary and ranked secondary endpoints

Intra-Cellular Therapies presents further data on ITI-007 for schizophrenia

FDA grants orphan drug designation for elamipretide for treatment of Barth syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...